Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on CDR132L for Heart Failure with Reduced Ejection Fraction and Left Ventricular Hypertrophy in Adults

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying heart failure in individuals who have a reduced or mildly reduced ability of the heart to pump blood, known as ejection fraction, along with a condition called left ventricular hypertrophy, which is a thickening of the heart's main pumping chamber. The study will test a treatment called CDR132L, which is a type of nucleic acid therapy. This treatment will be compared to a placebo to see how it affects the heart's structure and function.

The purpose of the study is to determine if CDR132L is more effective than a placebo in improving heart health in participants. The study will last for several months, during which participants will receive either the CDR132L treatment or a placebo, in addition to their usual heart failure care. The main focus will be on changes in a specific molecule called miR-132 over a 24-week period. Participants will be monitored for any changes in their heart condition and any side effects they may experience.

Throughout the study, participants will undergo regular check-ups to assess their heart's function and overall health. The study aims to provide valuable information on the potential benefits of CDR132L for people with heart failure and left ventricular hypertrophy, contributing to better treatment options in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria such as age, heart function, and overall health status.

    You will undergo tests like echocardiography to assess your heart's structure and function. Your body mass index and weight will also be measured.

  2. Step 2

    Randomization

    After confirming eligibility, you will be randomly assigned to receive either the study medication, CDR132L, or a placebo. A placebo is a substance with no active medication, used for comparison.

    This process is double-blind, meaning neither you nor the study team will know which treatment you are receiving.

  3. Step 3

    Treatment phase

    You will receive the assigned treatment every four weeks (Q4W) for a total of 24 weeks. The dosage for CDR132L is 00 mg/kg.

    During this phase, you will continue with your standard heart failure care as prescribed by your healthcare provider.

  4. Step 4

    Follow-up visits

    Throughout the study, you will have regular follow-up visits to monitor your health and the effects of the treatment.

    These visits will include assessments of your heart function and any side effects you may experience.

  5. Step 5

    End of treatment assessment

    At the end of the 24-week treatment period, a final assessment will be conducted to evaluate changes in your heart's structure and function.

    This will include measuring specific markers in your blood and conducting imaging tests.

  6. Step 6

    Extended follow-up

    After the treatment phase, you will continue to be monitored for any long-term effects or adverse events until week 60.

    This extended follow-up ensures your safety and helps gather comprehensive data on the treatment's impact.

Who can join the trial?

8 criteria

  • Age between 40 and 84 years old.
  • Have a documented history of heart failure symptoms for at least 180 days before the screening, requiring at least weekly use of oral diuretics (medications that help remove excess fluid from the body). Must be classified as New York Heart Association class II or III, which means experiencing some limitations in physical activity.
  • Be clinically stable and on optimized doses of heart failure medications for at least 30 days before joining the study.
  • Have a left ventricular ejection fraction (LVEF) of less than 50% as measured by an echocardiogram. LVEF is a measure of how well the heart pumps blood.
  • Have a left ventricular mass index (LVMi) greater than 88 g/m² for women and greater than 102 g/m² for men, as measured by an echocardiogram. LVMi is a measure of the size of the heart muscle.
  • Have a left atrial volume index (LAVi) of 29 mL/m² or more, as measured by an echocardiogram. LAVi is a measure of the size of the left atrium of the heart.
  • Have a body mass index (BMI) between 18.5 and 40 kg/m² and a body weight of 140 kg or less. BMI is a measure of body fat based on height and weight.
  • Have a level of NT-proBNP of 300 pg/mL or more, or 600 pg/mL or more if atrial fibrillation or flutter is present. NT-proBNP is a blood test that helps measure the severity of heart failure.

Who cannot join the trial?

8 criteria

  • Patients with a history of severe allergic reactions to any of the study medications.
  • Patients who have had a heart attack in the last 3 months.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe kidney disease.
  • Patients with severe liver disease.
  • Patients who are pregnant or breastfeeding.
  • Patients who are currently participating in another clinical trial.
  • Patients with any other medical condition that the study doctors think would make it unsafe to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CDR132L is an experimental medication being studied for its potential to help people with heart failure. Heart failure is a condition where the heart doesn't pump blood as well as it should. This medication is designed to target a specific molecule in the body called miR-132, which is thought to play a role in heart problems. By affecting this molecule, CDR132L aims to help improve the heart's function and structure, potentially leading to better outcomes for patients with heart failure. In this study, CDR132L is being tested to see if it can help reverse changes in the heart that occur with heart failure, especially in people whose heart muscle has become thicker than normal.

What is already known about the treatment

CDR132L – CDR132L is administered as an injection, given every four weeks, and is currently being studied in clinical trials to assess its safety and effectiveness. It is being researched for its potential to help people with heart failure, specifically those with reduced or mildly reduced heart function and thickened heart walls. The medication works by targeting a specific molecule in the body called miR-132, which is involved in heart function and structure. CDR132L is classified as a therapeutic agent aimed at reversing harmful changes in the heart, and it is still under investigation to confirm its benefits and safety.

Investigated diseases

  • Heart Failure with Reduced Ejection Fraction

    This condition occurs when the heart muscle is unable to pump blood effectively, leading to a decrease in the amount of blood ejected from the heart with each beat. Over time, the heart's ability to pump diminishes, causing symptoms such as fatigue, shortness of breath, and fluid retention. The heart chambers may become enlarged, and the walls of the heart may thicken. As the condition progresses, the heart's pumping capacity continues to decline, which can lead to further complications. The reduced ejection fraction is a key indicator of the severity of the condition. Management focuses on improving heart function and alleviating symptoms.

  • Heart Failure with Mildly Reduced Ejection Fraction

    This condition is characterized by a slightly reduced ability of the heart to pump blood, with an ejection fraction that is lower than normal but not as severely reduced as in other forms of heart failure. Symptoms may include mild fatigue, shortness of breath, and some fluid retention. The heart's pumping ability is compromised, but the reduction in ejection fraction is less pronounced. Over time, the heart may struggle to meet the body's demands, leading to a gradual worsening of symptoms. The condition requires monitoring to prevent further decline in heart function. Management aims to support heart health and maintain quality of life.

  • Left Ventricular Hypertrophy

    This condition involves the thickening of the walls of the heart's left ventricle, which is the main pumping chamber. The thickened heart muscle can become stiff, reducing the heart's ability to fill with blood and pump efficiently. Over time, this can lead to increased pressure in the heart and reduced blood flow to the body. Symptoms may not be immediately apparent but can include chest pain, dizziness, and shortness of breath. The condition often develops as a response to high blood pressure or other heart-related issues. Monitoring and management focus on addressing the underlying causes and preventing further heart damage.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-515797-27-00Protocol codeNN6706-8282Estimated enrolment212 patientsSponsorNovo Nordisk A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).